Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam ® 10%) in patients with immune thrombocytopenia

Hematology

Volumn 15, Issue 5, 2010, Pages 351-359

  Robak, Tadeusz ^a   Mainau, Claudia ^b   Pyringer, Barbara ^b   Chojnowski, Krzysztof ^a   Warzocha, Krzysztof ^c   Dmoszynska, Anna ^d   Straub, Jan ^e   Imbach, Paul ^f  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Octapharma Pharmazeutika Produktions GmbH   (Austria)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d Medical University of Lublin Klinika Hematoonkologii i Transplantacji Szpiku AM w Lublinie   (Poland)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Bleeding; immune thrombocytopenia; intravenous immunoglobulin; octagam 10 ; platelet count

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CHILL; CHRONIC DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; FEMALE; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS INFECTION; VITAL SIGN; VOMITING;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HEART RATE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 77957300876     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12719010991867     Document Type: Article

References (29)

1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133:364-374.
2. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009;146:585-596.
3. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.
4. EMEA. Report of EMEA Expert Meeting on the revisions of the core SPC and note for guidance for human normal immuonglobulin for intravenous administration (IVIg): 5-6 July 2006. London: European Medicines Agency, 2008.
5. British Society for Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-596.
6. American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997;126:319-326.
7. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231.
8. Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
9. Ochs HD, Pinciaro PJ. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004;24:309-314.
10. ®. Eur J Hosp Pharm 2004;4:75-77.
11. Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clin Exp Rheumatol 1996;14(Suppl 15):S115-S119.
12. Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16:1038-1047.
13. Haas J, Hommes OR. A dose comparison study of IVIg in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007;13:900-908.
14. Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroidresistant Crohn's disease. Z Gastroenterol 2007;45:605-608.
15. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133:247-251.
16. National Institutes of Health (NIH). Intravenous immunoglobulin: prevention and treatment of disease - NIH consensus development conference statement, 21-23 May 1990. 1990: 1-23.
17. Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. Eur Assoc Hosp Pharm Pract 2007;13:66-67.
18. Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 1984;6:355-361.
19. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984;5:348-361.
20. Bussel JB, Kimberly RP, Inman RD et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62:480-486.
21. Newland AC, Burton I, Cavenagh JD et al. Vigam-S, a solvent/detergent- treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura. Transfus Med 2001;11:37-44.
22. Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003;4:358-362.
23. Wolf HH, Davies SV, Borte M et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84:45-53.
24. Varga G, Volková Z, Leibl H et al. Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfus Med Hemother 2006;33:509-514.
25. Piguet D, Tosi C, Luthi JM, Andresen I, Juge O. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol 2008;152:45-49.
26. Robak T, Salama A, Kovaleva L et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 2009;14:227-236.
27. Julia A, Kovaleva L, Loria S et al. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura. Transfus Med 2009;19:260-268.
28. Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005;147:521-527.
29. Tamminga R, Berchtold W, Bruin M, Buchanan GR, Kuhne T. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol 2009;146:180-184.